Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
CRISPR THERAPEUTICS AG |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 71.51 USD | +4.17% | -0.14% | +75.92% | |
| Dec. 04 | CRISPR Therapeutics Focusing on Development of CAR T Cell Product Candidates CTX112, CTX131 | MT |
| Nov. 16 | Global markets live: Burberry, Palo Alto, Walmart, Cisco, Adobe, Microsoft... |  |
Financials (USD)
| Sales 2023 * | 276M | Sales 2024 * | 148M | Capitalization | 5.45B |
|---|---|---|---|---|---|
| Net income 2023 * | -290M | Net income 2024 * | -448M | EV / Sales 2023 * | 14,6x |
| Net cash position 2023 * | 1.42B | Net cash position 2024 * | 1.26B | EV / Sales 2024 * | 28,3x |
| P/E ratio 2023 * | -19,1x | P/E ratio 2024 * | -11,5x | Employees | 458 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 98.37% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +4.17% | ||
| 1 week | +2.20% | ||
| Current month | +7.16% | ||
| 1 month | +40.24% | ||
| 3 months | +41.52% | ||
| 6 months | +10.02% | ||
| Current year | +75.92% |
1 week
63.39
73.55
1 month
48.5576.19
Current year
37.5576.19
1 year
37.5576.19
3 years
37.55220.20
5 years
22.22220.20
10 years
11.63220.20
| Managers | Title | Age | Since |
|---|---|---|---|
Samarth Kulkarni
CEO | Chief Executive Officer | 44 | 2015 |
Raju Prasad
DFI | Director of Finance/CFO | 39 | Mar. 13 |
| Chief Tech/Sci/R&D Officer | 49 | 2022 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Doug Treco Treco
BRD | Director/Board Member | 65 | 2020 |
Simeon George
BRD | Director/Board Member | 45 | 2015 |
Ali Behbahani
BRD | Director/Board Member | 46 | 2015 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 10.82% | 323 M€ | -8.20% | - | |
| 8.55% | 2 M€ | -25.75% | ||
| 4.84% | 1 M€ | 0.00% | - | |
| 4.53% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-04 | 71.51 | +4.17% | 2,815,394 |
| 23-12-01 | 68.65 | +2.88% | 3,675,377 |
| 23-11-30 | 66.73 | -3.42% | 2,515,802 |
| 23-11-29 | 69.09 | -2.22% | 2,215,093 |
| 23-11-28 | 70.66 | -1.33% | 1,861,191 |
Delayed Quote Nasdaq, December 04, 2023 at 04:00 pm EST
More quotes
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Calendar
2024-02-12
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
71.51USD
Average target price
88.36USD
Spread / Average Target
+23.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +75.92% | 5 453 M $ | |
| +65.85% | 40 132 M $ | |
| +5.55% | 39 586 M $ | |
| -55.53% | 30 438 M $ | |
| -27.15% | 28 571 M $ | |
| +37.25% | 22 175 M $ | |
| -27.26% | 21 511 M $ | |
| +1.31% | 17 412 M $ | |
| -13.72% | 11 313 M $ | |
| -7.93% | 10 346 M $ |
